^
Association details:
| Biomarker: | BRIP1 L680fs*9 |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + veliparib (ABT-888) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Study of Veliparib and Nivolumab in Adults with Refractory Advanced Solid Tumor and Lymphoma
Published date:
11/09/2019
Excerpt:
One patient with refractory metastatic pancreatic carcinoma harboring a BRIP1 L680fs*9 mutation had SD after a 35-week follow-up.
Trial ID:
